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Abstract
Background: Hemodialysis (HD) patients are susceptible to extended spectrum beta-lactamase (ESBL)-producing
bacterial infections. Because the optimal treatment and clinical significance of ESBL-producing Klebsiella pneumoniae
(ESBL-Kp) HD access-related bacteremia remain unclear, we conducted this retrospective study to determine the
clinical outcomes of patients treated with either flomoxef or a carbapenem.
Methods: The eligibility criterion was fistula or graft- or catheter- related ESBL-Kp bacteremia in patients on
maintenance HD. The clinical characteristics and antibiotic management were analyzed. Outcome was determined
by mortality resulting from bacteremia during the 14-day period after the first positive blood culture for flomoxef-
susceptible ESBL-Kp.
Results: The 57 patients studied were predominantly elderly, malnourished, with a history of severe illnesses and
broad-spectrum antibiotic use before the onset of bacteremia, and with severe septicemia as determined by the Pitt
bacteremia score (PBS). The study population comprised 7 fistula, 8 graft, and 42 HD catheter-related bacteremia
(CRB) cases, and the mortality rate was high (36/57, 63.2%) in these 57 patients. Of 42 patients with CRB, those in the
deceased group (27/42, 64.3%) had significantly lower levels of serum albumin, longer prior hospital stay and
duration of catheter-dependent HD, and higher PBS than patients in the survived group. Failure to receive effective
antibiotics (flomoxef or a carbapenem) within 5 days after onset of bacteremia and treatment with flomoxef both
significantly contributed to higher mortality. Multivariate analyses revealed that flomoxef use, PBS, and catheter-
dependent HD >30 days were independently associated with increased mortality (OR, 3.52; 95% CI, 1.19–58.17, OR,
2.92; 95% CI, 1.36–6.26 and OR, 5.73; 95% CI, 1.21–63.2, respectively).
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Conclusions: Considering the high mortality rate, ESBL-Kp should be recognized as a possible pathogen in patients
on maintenance HD at high risk of acquiring HD access infections associated with ESBL-producing bacteria.
Carbapenems rather than flomoxef should be the therapy of choice in these critically vulnerable patients.
Keywords: Bacteremia, Carbapenems, Extended spectrum beta-lactamase, Flomoxef, Hemodialysis access, Klebsiella
pneumoniae
Background
Hemodialysis (HD) access-related infections are a major
cause of morbidity and mortality in HD patients; the re-
sponsible microorganisms, prevention and treatment strat-
egies, and outcome have been assessed in earlier studies
[1,2]. Gram-negative bacteria (GNB) have been reported in
up to 33% of cases with catheter-related bacteremia (CRB),
indicating that empiric antibiotic therapy should target
both gram-positive and gram-negative organisms [2].
Ignoring the possibility of GNB, especially those producing
extended spectrum beta-lactamase (ESBL), as mediators of
HD access-related infections places a considerable number
of patients at unwarranted risk.
Risk factors for the acquisition of ESBL infections have
been well studied and include—but are not limited to—HD,
old age, prolonged hospitalization, severe illness, poor nu-
tritional status, treatment in an intensive care unit (ICU),
and previous exposure to broad-spectrum antibiotics, with
overuse of extended-spectrum cephalosporins in the hos-
pital setting as one of the most important factors [3,4]. In
addition to the risk of immunocompromise, HD patients
may be rendered susceptible to ESBL-related infection by
frequent vascular catheterization, catheter manipulation,
and the need for broad-spectrum antibiotics during pro-
longed hospitalization, especially in the ICU setting.
The currently recommended therapy for infection caused
by ESBL-producing organisms consists of carbapenems
[4,5]. Cephamycins (i.e., cefmetazole, cefotetan, and flo-
moxef), characterized by their 7-α-methyoxy β-lactam,
have been reported to be highly active in vitro against
both low inocula (105–106 cfu/mL) and high inocula
(107–108 cfu/mL) of TEM- or SHV-producing Entero-
bacteriaceae [6]. Unfortunately, the use of cephamycins is
not universal but limited in some countries. In addition,
many controversies about optimal treatment exist, and
few clinical reports comparing the treatment efficacy of
cephamycins and carbapenems have been published [7].
The vast majority of Klebsiella pneumoniae (K. pneumo-
niae) infections are associated with hospitalization, and
ESBL-producing bacteria are reported to comprise a sig-
nificant percentage of nosocomial K. pneumoniae strains
[8]. In a retrospective study, treatment with either flo-
moxef or a carbapenem in patients with flomoxef-
susceptible ESBL-producing K. pneumoniae (ESBL-Kp)
bacteremia was reported to be similarly effective [9]. How-
ever, their clinical effectiveness and most appropriate anti-
biotic prescription strategies for HD access-related ESBL-
Kp bacteremia in patients on maintenance HD (MHD)
have not yet been established. We conducted this 7-year
retrospective study to compare the clinical outcomes of
patients treated with either flomoxef or a carbapenem, and
to gain a better understanding of the clinical significance
and impact of HD access-related ESBL-Kp bacteremia in
patients on MHD.
Methods
Study population and design
This retrospective study was conducted in a tertiary care
hospital with 950 MHD patients treated in the outpatient
department. MHD patients admitted during the 7-year
period from January 2001 to December 2007 who devel-
oped a nosocomial HD access-related infection secondary
to ESBL-Kp were included. The eligibility criterion was
HD access, including arteriovenous fistula or graft- or
catheter-related ESBL-Kp bacteremia. Only adult patients
with flomoxef-susceptible ESBL-Kp bacteremia who were
treated with either flomoxef or a carbapenem (meropenem
or imipenem) were included. For each included patient,
the prescribed flomoxef or a carbapenem was adminis-
tered for at least 2 days, starting within 5 days after receiv-
ing finalized blood culture results. The use of either
flomoxef or a carbapenem was left to the discretion of the
attending physician in each case. Details of the patients’
clinical course, biochemical data, sites of ESBL-Kp infec-
tion (blood, HD catheter tip, pus from HD catheter exit
site, and pus from fistula or graft wounds), and outcome
were obtained from medical charts. Individual patient
without blood culture that grew ESBL-Kp was excluded
because, in the absence of concurrent blood cultures from
the peripheral vein, there is a risk of enrolling patients sim-
ply representing colonization. Severely ill patients who died
rapidly without receiving a carbapenem or flomoxef for at
least two days were also excluded. Variables used for the
assessment of severity of illness included Pitt bacteremia
score (PBS), ICU stay at the time of bacteremia, and length
of prior hospital stay (LOS). Mortality resulting from
bacteremia within 14 days after the first positive blood
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culture that grew flomoxef-susceptible ESBL-Kp was used
to determine the outcome.
The study was approved by the institutional review
board of Kaohsiung Chang Gung Memorial Hospital
with the study ID: CGMH-IRB-100-2452B.
Microbiology
All K. pneumoniae isolates were identified by standard
methods, and the presence of ESBLs was evaluated using
the Clinical and Laboratory Standards Institute criteria
for ESBL screening and disc confirmation test [10].
Minimum inhibitory concentrations (MICs) ≤ 4 mg/L for
meropenem and ≤ 8 mg/L for flomoxef were considered
to indicate susceptibility [11,12].
Definitions
ESBL-Kp bacteremia was defined by the isolation of
ESBL-Kp from blood cultures. Nosocomial bacteremia
was defined as bacteremia occurring >48 h after admission
to the hospital. HD access infections were defined as local
signs (pus or redness) at the vascular access site with or
without a positive culture of catheter tip, pus, or a positive
blood culture with no known source other than the vascu-
lar access. Empiric antibiotic was defined as antibiotic
therapy started at the time blood cultures were drawn.
Effective antibiotics for flomoxef-susceptible ESBL-Kp
bacteremia included carbapenems and flomoxef. Signifi-
cant underlying disease was defined as a medical history
of diabetes mellitus, liver cirrhosis, malignancy, and con-
gestive heart failure.
Statistical analyses
All statistical analyses were performed using the Statistical
Package for Social Science program (SPSS for Windows,
Version 11.5; SPSS, Chicago, IL). Continuous variables
were each expressed as the mean± SD and were analyzed
using the Student t test. The statistical difference in the
frequency of occurrence of the variants in patients with
HD catheter-related bacteremia between survived and
deceased subgroups was assessed by the chi-square test or
Fisher’s exact test. A logistic regression model was used to
estimate the effects of multiple factors associated with
mortality in the univariate analyses. Variables with P≤ 0.1
in univariate analysis between patients of deceased and
survived groups were entered for further assessment. Esti-
mated ORs and 95% CI were obtained from this model.
For all analyses, two-sided tests of significance were used
with P < 0.05 considered significant.
Results
A total of 57 MHD patients with HD access-related
bacteremia who met the criteria were identified during the
study period. The clinical courses and characteristics of
these patients are summarized in Table 1. In addition to 42
patients with HD CRB, there were 7 patients with fistula
and 8 patients with graft-related bacteremia. Most of these
patients were male and elderly, with a history of severe ill-
ness that included ICU stay, shock, or intubation during
their prolonged hospitalization prior to the onset of
bacteremia. Significant underlying diseases and prior use of
broad-spectrum antibiotics were also highly prevalent.
Most patients were initially hospitalized due to the onset of
an infectious disease (34/57, 59.6%). At the onset of
bacteremia, poor nutritional status and critical illness,
defined as PBS greater or equal to 4 points, were noted in
these patients. Twenty-nine (29/57, 50.9%) patients were
accommodated in an ICU at the time of the detection of
bacteremia. The overall mortality rate was high (36/57,
63.2%), and patients with graft infection had the highest
PBS and the highest rate of mortality (6/8, 75%). With re-
gard to the use of empiric antibiotics, the majority (36/57,
63.2%) did not receive effective antibiotic therapy, consist-
ing of either flomoxef or a carbapenem within 5 days after
the onset of bacteremia. A total of 50.9% (29/57) patients
were treated with flomoxef and 49.1% (28/57) with carbape-
nems as effective antibiotics.
In addition to antibiotic treatment, surgical interventions
(wound debridement and/or removal of infected fistula or
graft) were performed in 7 of 15 patients with fistula or
graft infection. All HD catheters related to ESBL-Kp
bacteremia in 42 patients were removed after the onset of
bacteremia. The extent and perioperative risk of surgery
may affect survival of patients with fistula or graft infection
but their effects were difficult to estimate. We believe bias
and confounding factors could be reduced if we only ana-
lyzed 42 patients, all with catheter-related bacteremia.
Most of the 42 patients with HD CRB were elderly, exhi-
bited low levels of serum albumin and hemoglobin at the
onset of bacteremia, and had a history of prolonged hospi-
talization. Patient demographics are summarized in Table 2.
Of the 42 patients included in the study, those in the
deceased group had significantly lower levels of serum albu-
min, a longer hospital stay, and catheter-dependent HD.
The mortality rate was high (27/42, 64.3%). Concerning the
severity of the septicemia, a significantly higher PBS and a
trend toward a longer ICU stay were noted in the deceased
group. Antibiotic strategies also significantly affected the
outcome. Treatment with flomoxef or failure to receive ef-
fective antibiotic therapy within 5 days after the onset of
bacteremia was associated with increased mortality.
Variables that were determined to be significantly asso-
ciated with mortality at 14 days after the first positive blood
culture result by univariate analysis were subjected to
multivariate analysis. Flomoxef use, higher PBS, and
catheter-dependent HD>30 days were independently asso-
ciated with increased mortality (OR, 3.52; 95% CI, 1.19–
58.17; OR, 2.92; 95% CI, 1.36–6.26 and OR, 5.73; 95% CI,
1.21–63.2, respectively).
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Discussion
There is limited information regarding the clinical charac-
teristics associated with HD access-related ESBL-Kp
bacteremia in MHD patients. Most of the patients with
bacteremia in the present study were elderly, malnour-
ished, and had a history of severe illness and prolonged
hospitalization. These patients were also critically ill, as
determined by PBS, and had high prevalence rates of sig-
nificant underlying diseases and ICU stay at the time of
the onset of bacteremia; therefore, they had a high mortal-
ity rate(36/57, 63.2%). Although broad-spectrum antibiotic
treatment prior to the onset of bacteremia was also highly
prevalent, its contribution to the acquisition of ESBL in-
fection and effect on patient outcome were not analyzed;
this might contribute to an epidemiological bias. Only
36.8% of these critically ill patients received empiric effect-
ive antibiotics within 5 days after the first positive blood
culture for ESBL-Kp, which may have contributed to the
high mortality rate.
Previous studies have demonstrated vascular access
accounts for 48–73% of bacteremia in HD patients [2]. In
the present study, both longer LOS and a lower serum al-
bumin level were associated with high mortality in patients
with CRB. Prolonged hospitalization has been recognized
as a risk factor for ESBL infection in prior studies, which
reported a mean time to acquisition of ESBL-Kp bacteremia
of more than 1 month [13]. Hypoalbuminemia was found
to increase the likelihood of a recurrent episode of CRB
among patients treated for an initial CRB [1]. In the present
study, the duration of catheter-dependent HD before
bacteremia was on an average longer than 1 month, and
catheter-dependent HD≥30 days was a significant inde-
pendent risk factor for increased mortality by multivariate
analysis. These findings suggest that shortening the dur-
ation of catheter-dependent HD may decrease the probabil-
ity of CRB secondary to ESBL-producing bacteria and
improve the prognosis. It is not surprising to find that
higher PBS was independently associated with increased
mortality. There was also a trend toward a longer ICU stay
at the time of bacteremia in the deceased group. Because
MHD patients with HD access-related ESBL-Kp bacteremia
were mostly immunocompromised and critically ill, their
mortality rate was determined by these parameters, which
reflected the severity of the septicemia.
For ESBL infections, there are both a higher clinical
failure rate [14] and mortality rate [13] associated with
Table 1 Comparisons of demographic and clinical data between the groups of different HD access related ESBL-Kp
bacteremia
Source of infection HD catheter Fistula Graft ALL
Case No 42 7 8 57
Male (%) 33 (78.6) 6 (85.7) 6 (75) 45 (78.9)
Age, years 64.8 ± 10.0 61 ± 10.5 65.1 ± 7.8 64.4 ± 9.5
Patients aged >65 years (%) 24 (57.1) 3 (42.9) 5 (62.5) 32 (56.1)
Admission for infectious diseases (%) 23 (54.8) 5 (71.4) 6 (75) 34 (59.6)
Significant underlying diseases (%)
Diabetes mellitus 15 (35.7) 4 (57.1) 7 (87.5) 26 (45.6)
Liver cirrhosis 5 (11.9) 1 (14.3) 2 (25) 8 (14)
Congestive heart failure 10 (23.8) 3 (42.9) 5 (62.5) 18 (31.6)
Malignancy 4(9.5) 1 (14.3) 1 (12.5) 5 (8.8)
Comorbid conditions (%)
Poor nutritiona 42 (100) 7 (100) 8 (100) 57 (100)
Prior antibiotic useb 37 (88.1) 6 (85.7) 7 (87.5) 50 (87.7)
Previous severe illnessc 35 (83.3) 6 (85.7) 6 (75) 47 (82.5)
Prolonged (>30 days) hospitalization 33 (78.6) 5 (71.4) 6 (75) 44 (77.2)
Prior use of 3rd-generation cephalosporin 27 (64.3) 5 (71.4) 6 (75) 38 (66.7)
ICU stay at or after the onset of bacteremia 20 (47.6) 4 (57.1) 5 (62.5) 29 (50.9)
Pitt bacteremia score 5.29 ± 1.67 5 ± 1.73 6.38 ± 2.26 5.4 ± 1.78
ABx after onset of bacteremiad
Effective ABx within 5 days (%) 15 (35.7) 3 (42.9) 3 (37.5) 21 (36.8)
Use flomoxef/IMP /MEP as effective ABx(%) 19(45)/13(31)/ 10(24) 4(57)/3(43)/ none 6 (75)/none/ 2(25) 29(51)/16(28)/ 12(21)
Mortality (%) 27 (64.3) 3 (42.9) 6 (75) 36 (63.2)
a albumin < 3.5 g/dL; b including extended-spectrum cephalosporins, aztreonam, fluoroquinolones, trimethoprim/sulfamethoxazole, or aminoglycosides; c includes
shock, intubation and ICU stay; d Abx: antibiotics, IMP: imipenem, MEP: meropenem.
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Table 2 Comparisons of demographic and clinical data between the deceased and survived groups of the 42 patients with CRB; Variables with a p-value < 0.1
by univariate analysis were subjected to multivariate analysis
Variable Survived group Deceased group P Total
n = 15 n= 27 n=42
Mean age, years 63.2 ± 7.6 65.7 ± 10.3 NS 64.8 ± 10.0
Male (%) 12/15 (80) 21/27 (77.8) NS 33/42 (78.6)
Patients aged >65 years (%) 8/15 (53.3) 16/27 (59.3) NS 24/42 (57.1)
Flomoxef treatment (%)a 3 (20) 16 (59.3) 0.009 19 (45.2)
Treatment within 5 days 9 (60) 6 (22.2) 0.021 15 (35.7)
Pitt bacteremia score, mean± SD a 4.27 ± 1.03 5.85 ± 1.7 0.002 5.29 ± 1.67
Serum albumin(g/dL), mean± SD 2.70 ± 0.31 2.12 ± 0.42 0.046 2.33 ± 0.61
Hemoglobin(g/dL), mean± SD 8.98 ± 0.71 9.13 ± 1.92 NS 9.08 ± 1.56
Hospital days before onset, mean± SD 49 ± 35.8 116.9 ± 87.5 0.039 92.6 ± 79.6
No. of hospital days before onset > 30 (%) 8/15 (53.3) 23 (85.2) 0.034 30/42 (71.4)
Duration of catheter-dependent HD(days) 24.5 ± 9.2 43.6 ± 12.3 0.048 36.6 ± 10.2
No. of catheter-dependent HD days > 30 (%)a 4 (26.7) 18 (66.7) 0.023 22 (52.4)
ICU stay at the time of bacteremia 4 (26.7) 16 (59.3) 0.058 20 (47.6)



















cephalosporin treatment. Furthermore, ESBL-producing
bacteria are frequently resistant to many classes of
beta-lactam and non-beta-lactam antibiotics, including
cefepime [15], beta-lactam/beta-lactamase inhibitor combi-
nations, fluoroquinolones [16], and aminoglycosides [17].
The emergence of multi-drug resistance in these viru-
lent pathogens has significantly hampered the effort to
devise effective empiric or directed antibiotic treatment
regimens, and is associated with high treatment failure
rates. Unfortunately, most of our patients initially received
ineffective empiric antibiotics, including extended-
spectrum cephalosporins, which increased the diffi-
culty of further treatment and led to a high treatment
failure and mortality rates.
Although carbapenems have been recommended for the
treatment of infections caused by ESBL-producing organ-
isms, extensive use of these antibiotics may result in the
outbreak of infections related to carbapenem-resistant
strains such as Acinetobacter baumanii [18], Pseudomonas
aeruginosa [19], and Stenotrophomonas maltophilia [20],
and it poses challenging infection-control issues. Flo-
moxef is unique among cephamycins in having a
difluoromethylthio-acetamido group at position 7,
which improves its in vitro activity against ESBL-
producing Enterobacteriaceae [6,21]. Flomoxef was
also shown to be as clinically effective as a carbapenem
for the treatment of flomoxef-susceptible ESBL-Kp
bacteremia in terms of clinical outcome and compar-
able results of time-kill studies regardless of the inocu-
lum size of 105 or 107 cfu/mL [9]. Although this study
was limited by its retrospective design and small sam-
ple size, it provides insight into the possibility of using
a cephamycin for infections caused by ESBL-producing
bacteria. However, the efficacy of these agents for the
treatment of HD access-related ESBL-Kp bacteremia in
MHD patients is still unclear.
The use of effective antibiotics such as carbapenems
during the 5-day period after the onset of bacteremia due
to an ESBL-producing organism has been reported to be
associated with lower mortality [22]. In the present study,
treatment with effective antibiotics within 5 days after the
onset of bacteremia and the use of carbapenems improved
the prognosis in patients with CRB. The choice of antibio-
tics is critical, in the light of our finding that treatment
with flomoxef was an independent risk factor for
increased mortality in these vulnerable patients by multi-
variate analyses. The lower percentage of patients receiv-
ing effective empiric antibiotics may reflect our collective
unawareness of the significance of these emerging strains
and the very limited information regarding this issue.
Conclusion
This is the first study to report the clinical implications
of nosocomial HD access-related ESBL-Kp bacteremia.
We stress that ESBL-Kp should be considered as a pos-
sible pathogen in HD access-related infections. Because
of the high antimicrobial resistance and high mortality
rate in these more vulnerable and critically ill patients,
we suggest carbapenems rather than flomoxef as the first
choice for empiric or directed therapy in HD patients at
high risk for HD access-related ESBL-Kp infections.
Shortening the duration of catheter-dependent HD also
improved the outcome.
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